US Patent

US11850248 — Therapies with 3rd generation EGFR tyrosine kinase inhibitors

Method of Use · Assigned to Yuhan Corp · Expires 2041-08-01 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects therapies using lazertinib mesylate to treat non-small cell lung cancer.

USPTO Abstract

The present invention relates to therapies with 3 rd generation EGFR tyrosine kinase inhibitors. Embodiments of the invention relate to the administration of lazertinib to patients diagnosed with non-small cell lung cancer (NSCLC).

Drugs covered by this patent

lazertinib-mesylate (LAZERTINIB MESYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3985`	—	lazertinib-mesylate
`U-3985`	—	lazertinib-mesylate

Patent Metadata

Patent number: US11850248
Jurisdiction: US
Classification: Method of Use
Expires: 2041-08-01
Drug substance claim: No
Drug product claim: No
Assignee: Yuhan Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.